Live Breaking News & Updates on Dejan juric

Stay informed with the latest breaking news from Dejan juric on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Dejan juric and stay connected to the pulse of your community

Voices of Hope passes $1M in donations to cancer research with record-breaking 2023

Voices of Hope passes $1M in donations to cancer research with record-breaking 2023
lowellsun.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lowellsun.com Daily Mail and Mail on Sunday newspapers.

Dana-farber-cancer-institute , Massachusetts , United-states , Boston , Andover , Dana-siegal , Dejan-juric , Greg-chastain , Termeer-center , Summer-youth-program , Belfer-institute-for-applied-sciences , Hospital-termeer-center

Voices of Hope to reach $1M in donations

ANDOVER — At first they sang to remember, now they also sing to celebrate.

Boston , Massachusetts , United-states , Manhattan , New-york , Ballard-vale-united-church , Andover , Adrianne-ramos , Casandra-mcintyre , Cheryl-bentyne , Dejan-juric , Frank-moran

Genetic mutation diminishes drug response in some cancer patients

Researchers at Mass General Brigham have discovered a key mutation that may be a driving factor in resistance to certain drugs used to treat cancer.

Dejan-juric , Therapies-investigational-cancer-therapeutics-program , Termeer-center , Cancer-center , Boston-based-mass-general-brigham , Targeted-therapies , Investigational-cancer-therapeutics-program , Mass-general-cancer , Pi3k , Reast-cancer , Lpelisib , Utation

Researchers identify the mutations that drive resistance to PI3K inhibitors in breast cancer, find they can be overcome

Researchers identify the mutations that drive resistance to PI3K inhibitors in breast cancer, find they can be overcome
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

United-states , Dejan-juric , Ryan-corcoran , Andreas-varkaris , Termeer-center , Cancer-center , Gastrointestinal-cancer-center , Therapies-investigational-cancer-therapeutics-program , Cancer-discovery , Mass-general-cancer-center , Mass-general-brigham , Ferran-fece-de-la-cruz

TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results

TransCode Therapeutics Reports Business Progress and Second Quarter 2021 Financial Results
apnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from apnews.com Daily Mail and Mail on Sunday newspapers.

Massachusetts , United-states , Susan-duggan , Judy-carmody , Dustan-bonnin , Tom-fitzgerald , Josh-rappaport , Michael-dudley , Dejan-juric , Subrata-ghosh , Company-july , Investigational-cancer-therapeutics-program-at-massachusetts

José Manuel Baselga (1959–2021)

José Manuel Baselga, renowned oncologist, died on 21 March at the age of 61 at his home in La Cerdanya, a beautiful Catalan county surrounded by the Spanish and French Pyrenees. Possibly the greatest drug developer of the past two decades, José was famous for, in his own words, “going to places and changing things.” Throughout his career, he transformed oncology practice and made the development of new treatments his mission.
Born in Barcelona, Spain, on 3 July 1959, José was raised close to the Vall d'Hebron Hospital, an institution on which he would later leave his mark. He graduated from Universitat Autònoma de Barcelona in 1982 with an MD and then fulfilled his military service duty before starting his residency at the Vall d'Hebron Hospital in 1985. With a year left in his residency, José moved to the United States to work at Kings County Hospital in Brooklyn, New York. According to his sister Eulalia, he lived in a modest apartment with windows that would not close in winter, but the accommodations were good enough given that he was rarely home. José would spend his weekends and vacation time at Memorial Sloan Kettering Cancer Center (MSK) running lab experiments. He then moved full time to MSK under the mentorship of oncologists John Mendelsohn and Larry Norton. Together, they worked on newly identified antibodies targeting epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2), the predecessors of the anticancer therapies cetuximab, approved for the treatment of both colorectal and head and neck cancers, and trastuzumab, which drastically changed the prognosis of HER2-positive breast cancer patients. His work at MSK also earned him a PhD from Universitat Autònoma de Barcelona in 1992.

France , Massachusetts , United-states , New-york , Memorial-sloan-kettering-cancer-center , Hebron , Israel-general , Israel , Brooklyn , Boston , Spain , Barcelona

Scientists uncover mutations that make cancer resistant to therapies targeting KRAS

E-Mail
BOSTON - A gene called KRAS is one of the most commonly mutated genes in all human cancers, and targeted drugs that inhibit the protein expressed by mutated KRAS have shown promising results in clinical trials, with potential approvals by the U.S. Food and Drug Administration anticipated later this year. Unfortunately, cancer cells often develop additional mutations that make them resistant to such targeted drugs, resulting in disease relapse. Now researchers led by a team at Massachusetts General Hospital (MGH) have identified the first resistance mechanisms that may occur to these drugs and identified strategies to overcome them. The findings are published in

Boston , Massachusetts , United-states , American , Mustafa-sakhi , Samuel-klempner , Mohammed-syed , Giulia-siravegna , Aaron-hata , Meagan-ryan , Jochen-lennerz , Chendi-li